Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Scopolamine for Motion Sickness
NCT02155309Phase 3Terminated
- Sponsor
- Defender Pharmaceuticals
- Start
- Jun 2014
- Primary completion
- Mar 2016
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of scopolamine in motion sickness, sponsored by Defender Pharmaceuticals. Started Jun 2014; status: terminated.
02
Drugs
scopolamine
03
Conditions
motion sickness
Beyond the preview
Go deeper on NCT02155309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02155309.